Understanding and treating developmental brain disorders
Neurochlore is a Marseille based, privately-owned biotech company. In Europe, Neurochlore has developed Bumetanide, a registered highly specific inhibitor of the chloride modulator NKCC1, to treat autism in children and adolescents.
Our research aims at determining brain development alterations that lead to Autism Spectrum Disorders (ASD) and other Neurodevelopmental Disorders and identifying therapeutic targets.
Our four research facilities provide Neurochlore investigators with state of the art equipment and software that along with our technical and scientific expertise allow for optimal research project development.
These techniques aim to observe electric currents of neurons and neuronal networks.
Immunohistochemistry uses fluorescent antibodies to localize a target protein inside neurons.
Clearing protocol is based on solubilizing lipids, leading to a transparent brain. Fluorescent antibodies are then used to localize specific proteins.
These studies analyze behaviors of animal models to better understand pathologies and evaluate treatment efficiency.